Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-3: Nivolumab in combination with TACE/TAE for intermediate stage hepatocellular carcinoma
2018-000004-42Phase 2Unknown
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Status: unknown.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-000004-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000004-42.